William John Sibold, President and Chief Executive Officer of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), executed a sale of 1,663 shares of the companys common stock on March 6, according to a Form 4 filed with the Securities and Exchange Commission. The shares were sold at $431.94 apiece, producing total proceeds of $718,316.
The filing states the disposition was carried out to meet tax withholding obligations associated with the vesting of restricted stock units and was not discretionary. At the time of the report, Madrigals shares were trading around $433 and the company carried an approximate market capitalization of $10 billion. After the sale, Sibold is recorded as directly owning 161,829 shares of Madrigal Pharmaceuticals.
In related filings dated March 4, Sibold also acquired 14,995 shares of common stock that were recorded with a value of $0. The filing further shows he received 18,743 stock options - the right to buy shares - with an exercise price of $434.80. Those options carry an expiration date of 2036-03-04.
Earnings and analyst context
Madrigal disclosed its fourth-quarter 2025 results, registering an earnings-per-share (EPS) loss of $2.57, which fell short of the consensus forecast of a -$0.60 EPS. Revenue, however, came in ahead of expectations at $321.1 million versus the anticipated $310.82 million.
Following the release, Truist Securities reiterated its Buy rating on Madrigal and maintained a price target of $640.00, noting continued revenue growth as the commercial launch of Rezdiffra advances. H.C. Wainwright also maintained a Buy rating with a $620.00 price target, highlighting that Rezdiffra has generated nearly $1 billion in net sales seven quarters into its commercial launch. Both brokerages described Madrigal as a strong competitor in what they termed a largely unpenetrated market.
These developments underscore a mixed set of signals for investors: management-level stock activity tied to compensation tax obligations and quarterly results that combine a revenue beat with a material EPS miss. The analyst commentary included with the earnings release emphasizes commercial momentum for Rezdiffra while acknowledging the headline shortfall in per-share profitability.
Summary
Sibold's sale on March 6 was executed to satisfy tax liabilities from RSU vesting and was not a discretionary trade. The company reported stronger-than-expected revenue but a worse-than-expected EPS for Q4 2025. Major brokerages reiterated Buy ratings and cited Rezdiffra's ongoing commercial traction.